News
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...
Drug Research
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced multiple advancements in its 4-1BB bispecific antibody portfolio. Stimulation of 4-1BB is a promising therapeutic strategy for improving the current immunotherapy for cancers....
Drug Research
Batavia to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine
Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the...
Drug Research
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allow Altesa to develop and...
News
New Analysis Supports Medisafe’s Impact on Medication Persistence, Adherence
Medisafe, a leading digital drug companion company, announced the findings from two validation studies examining the impact of its digital drug companion on persistence to specialty medications (Rx). Led by Komodo Health, the analysis used real-world patient data to...
Drug Research
Oxford researchers launch HIV vaccine trial
The University of Oxford has launched a Phase I trial of a novel mosaic vaccine targeting a ‘broad range’ of HIV variants.
The HIV-CORE 0052 trial, part of the European Aids Vaccine Initiative, will involve 13 healthy HIV-negative adults aged...
News
Fenbendazole dosage
The dosage of Fenbendazole depends upon the health condition of the patient, already prescribed medicines, and/or chemotherapy. Dosage may vary for every human being.
Dosage guide:
Note: Consultation with a professional is very important. The dosage depends on chemotherapy, additional drugs,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















